Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02059057
Other study ID # CLN0016
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date December 2013
Est. completion date July 26, 2019

Study information

Verified date July 2021
Source Boston Scientific Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Crossover study for patients who were randomized to the Control Group in CLN0009 (NCT01608490).


Description:

Provide LVRC procedure to qualifying subjects who were enrolled as Control Subjects in and completed the Lung Volume Reduction Coil Treatment in Patients with Emphysema (RENEW) Study, CLN0009, and obtain safety and effectiveness data on these patients.


Recruitment information / eligibility

Status Terminated
Enrollment 102
Est. completion date July 26, 2019
Est. primary completion date June 2017
Accepts healthy volunteers No
Gender All
Age group 36 Years and older
Eligibility Inclusion Criteria: 1. Subject was enrolled as a Control Subject in and completed all required study assessments through the 12 month visit for the Lung Volume Reduction Coil Treatment in Patients with Emphysema (RENEW) Study, CLN0009. 2. Subject has post-bronchodilator FEV1 =45% predicted. 3. Subject has residual volume (RV) =175% predicted. 4. Subject has stopped smoking for at least 8 weeks prior to entering the study, as confirmed by a Cotinine test or other appropriate diagnostic test. 5. Subject has read, understood and signed the Informed Consent form. 6. Subject has received Pneumococcal and Influenza vaccinations consistent with local recommendations and/or policy. Exclusion Criteria: 1. Subject has severe homogeneous emphysema as determined by the Core Radiology Lab 2. Subject has co-morbidities that may significantly reduce subject's ability to improve exercise capacity (e.g. severe arthritis, planned knee surgery) or baseline limitation on 6MWT is not due to dyspnea. 3. Subject has a change in FEV1 >20% (or, for subjects with pre-bronchodilator FEV1 below 1 L, a change of > 200 mL) post-bronchodilator, unless investigator can confirm by other means that subject does not have asthma. 4. Subject has DLCO <20% of predicted. 5. Subject has severe gas exchange abnormalities as defined by: PaCO2 >55 mm Hg PaO2 <45 mm Hg on room air (High altitude criterion: PaO2 <30 mm Hg) 6. Subject has a history of recurrent clinically significant respiratory infections, defined as 3 hospitalizations for respiratory infection during the year prior to enrollment. 7. Subject has severe pulmonary hypertension. If pulmonary hypertension is present, "severe" is defined by right ventricular systolic pressure >50 mm Hg via right heart catheterization and/or echocardiogram. 8. Subject has an inability to walk >140 meters (150 yards) in 6 minutes. 9. Subject has evidence of other severe disease (such as, but not limited to, lung cancer or renal failure), which in the judgment of the investigator may compromise survival of the subject for the duration of the study. 10. Subject is pregnant or lactating, or plans to become pregnant within the study timeframe. 11. Subject has an inability to tolerate bronchoscopy under moderate sedation or general anesthesia. 12. Subject has clinically significant bronchiectasis. 13. Subject has giant bullae >1/3 lung volume. 14. Subject has had previous LVR surgery, lung transplantation, lobectomy, LVR devices or other devices to treat COPD in either lung. 15. Subject has been involved in pulmonary drug or device studies within 30 days prior to this study, with the exception of the RENEW Study. 16. Subject is taking >20 mg prednisone (or equivalent dose of a similar steroid) daily. 17. Subject requires high level chronic immunomodulatory therapy to treat a moderate to severe chronic inflammatory autoimmune disorder. 18. Subject is on an antiplatelet agent (such as Plavix) or anticoagulant therapy (such as heparin or Coumadin) which cannot be stopped for seven (7) days prior to procedure. 19. Subject has a sensitivity or allergy to nitinol (nickel-titanium) or its constituent metals. 20. Subject has a known sensitivity to drugs required to perform bronchoscopy. 21. Subject has been diagnosed with alpha-1 antitrypsin deficiency (AATD). 22. Subject has any other disease, condition(s) or habit(s) that would interfere with completion of study and follow up assessments, would increase risks of bronchoscopy or assessments, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes. -

Study Design


Related Conditions & MeSH terms


Intervention

Device:
LVRC System


Locations

Country Name City State
Canada Institut Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ) Quebec
France Centre Hospitalier Universitaire de Nice Nice
France CHU de Reims - Hopital Maison Blanche Reims
Netherlands University Medical Center Groningen Groningen
United Kingdom Royal Brompton Hospital & Chelsea Westminster London
United States University of Michigan Health System Ann Arbor Michigan
United States University of Alabama Lung Health Center Birmingham Alabama
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States Medical University of South Carolina Charleston South Carolina
United States Northwestern University Chicago Illinois
United States The Cleveland Clinic Cleveland Ohio
United States Duke University Medical Center Durham North Carolina
United States University of Florida Gainesville Florida
United States Pulmonary, Critical Care & Sleep Medicine Consultants,PCCS/St. Luke's Episcopal Hospital Houston Texas
United States Cedars Sinai Medical Center Los Angeles California
United States University of Wisconsin School of Medicine & Public Health Madison Wisconsin
United States El Camino Hospital/Palo Alto Medical Foundation Mountain View California
United States Yale University School of Medicine - Yale New Haven Hospital New Haven Connecticut
United States New York Presbyterian Columbia University Medical Center New York New York
United States Illinois Lung and Critical Care Institute Peoria Illinois
United States Temple Philadelphia Pennsylvania
United States Emphysema COPD Research Center, University of Pittsburgh Pittsburgh Pennsylvania
United States Mayo Clinic Rochester Minnesota
United States University of Texas Health Sciences Center at San Antonio San Antonio Texas
United States Franciscan Research Center Tacoma Washington

Sponsors (2)

Lead Sponsor Collaborator
Boston Scientific Corporation PneumRx, Inc.

Countries where clinical trial is conducted

United States,  Canada,  France,  Netherlands,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Change in Six Minute Walk Test (6MWT) Mean absolute change from baseline to12 months. The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is allowed to self-pace and rest as needed as they traverse back and forth along a marked walkway. Change in Baseline to 12 months
Secondary Mean Percent Change in Forced Expiratory Volume in One Second (FEV1) The forced expiratory volume in one second (FEV1) measurement shows the amount of air a person can forcefully exhale in one second. Typically, lower FEV1 scores show more severe stages of lung disease. A positive change in FEV1 indicates improvement in lung function. Change in Baseline to 12 months
Secondary Mean Change in Residual Volume (RV) Residual volume is the amount of air that remains in a person's lungs after fully exhaling. A decrease in residual volume indicates improvement in patients with higher residual volume measures. Change in Baseline to 12 months
Secondary Mean Change in St. Georges Respiratory Questionnaire (SGRQ) Measure Description: The SGRQ is designed to measure health impairment in patients with asthma and COPD.
It consists of 50 items and has two parts: Part I (Symptoms): several scales; Part II (Activity and Impacts): dichotomous (true/false) except last question (4-point Likert scale)
Scores range from 0 to 100, with higher scores indicating more limitations.
A negative change in score indicates improvement, with a mean change of 4 points being the minimal important difference.
Change in Baseline to 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05825261 - Exploring Novel Biomarkers for Emphysema Detection
Completed NCT02914340 - REACH SVS Control Patient Cross-Over Study N/A
Completed NCT02999685 - Home-based Health Management of Chronic Obstructive Lung Disease (COPD) Patients N/A
Completed NCT02238327 - Longitudinal Evaluation of HIV-associated Lung Disease Phenotypes
Completed NCT02232841 - Electrical Impedance Imaging of Patients on Mechanical Ventilation N/A
Completed NCT01615484 - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability N/A
Withdrawn NCT01908933 - Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema Phase 3
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Completed NCT01710449 - Evaluation of Regional Ventilation Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen Phase 1
Completed NCT00475007 - Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema N/A
Suspended NCT00523094 - Vibration Response Imaging (VRI) in Patients That Are Candidates for Undergoing Pulmonary Operation Procedure N/A
Recruiting NCT00129350 - Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation Phase 1
Completed NCT01953523 - Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions N/A
Completed NCT00000621 - Feasibility of Retinoic Acid Treatment in Emphysema (FORTE) Phase 2
Completed NCT00005292 - Alpha1-antitrypsin Deficiency Registry N/A
Recruiting NCT04537182 - Surgical Compared to Bronchoscopic Lung Volume Reduction in Patients With Severe Emphysema N/A
Active, not recruiting NCT02713347 - Advancing Symptom Alleviation With Palliative Treatment N/A
Recruiting NCT04302272 - STRIVE Post-Market Registry Study
Completed NCT04435327 - Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Completed NCT03636347 - A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. Phase 2